Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.760
+0.070 (2.60%)
Dec 24, 2025, 1:00 PM EST - Market closed
Cellectar Biosciences Analyst Ratings
Total Analysts
1
Consensus Rating
Hold
Price Target
n/a
Upside
n/a
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $420 → $360 | Buy | Maintains | $420 → $360 | +12,943.48% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $420 | Buy | Reiterates | $420 | +15,117.39% | Oct 11, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $600 → $840 | Strong Buy | Maintains | $600 → $840 | +30,334.78% | Mar 28, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $330 → $360 | Buy | Reiterates | $330 → $360 | +12,943.48% | Mar 28, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $600 | Strong Buy | Reiterates | $600 | +21,639.13% | Mar 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $120 | Strong Buy | Maintains | $90 → $120 | +4,247.83% | Nov 4, 2022 |
| Oppenheimer | Oppenheimer | Buy Initiates $1,650 | Buy | Initiates | $1,650 | +59,682.61% | Jul 18, 2022 |
| Oppenheimer | Oppenheimer | Buy Initiates $1,500 | Buy | Initiates | $1,500 | +54,247.83% | Jul 1, 2020 |
| Maxim Group | Maxim Group | Strong Buy Initiates $900 | Strong Buy | Initiates | $900 | +32,508.70% | Jun 23, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3,000 | Strong Buy | Initiates | $3,000 | +108,595.65% | Jan 21, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3,300 | Strong Buy | Initiates | $3,300 | +119,465.22% | Sep 13, 2019 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $8,100 | Strong Buy | Initiates | $8,100 | +293,378.26% | Dec 21, 2016 |